Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Immune checkpoint inhibitors may induce flares in patients with pre-existing autoimmune disease

27 Nov 2019

The initiation of immune checkpoint inhibitors (ICIs) for cancer in patients with pre-existing autoimmune disease appears to frequently lead to flares or immune-related adverse effects (IRAEs) that are mostly manageable, as shown in a study.

Researchers reviewed the medical records of 112 cancer patients with pre-existing autoimmune disease who were receiving ICIs. These patients were followed for a median of 8 months for the occurrence of flare, other IRAEs and cancer response.

Psoriasis was the most frequent pre-existing autoimmune disease (n=31), followed by rheumatoid arthritis (n=20) and inflammatory bowel disease (n=14). There were 24 patients (22 percent) on immunosuppressive therapy at ICI initiation.

A total of 79 patients (71 percent) developed autoimmune disease flare and/or other IRAE(s), including flare of pre-existing autoimmune disease in 53 (47 percent) and/or other IRAE(s) in 47 (42 percent), with a need for immunosuppressive therapy in 48 (43 percent) and permanent discontinuation of ICI in 24 (21 percent) patients.

On multivariable analysis, receipt of immunosuppressive therapy at ICI initiation was associated with shorter median progression-free survival (PFS; 3.8 months vs 12 months; p=0.006). Median PFS was also shorter in the presence of a flare of pre-existing autoimmune disease or other IRAE, with a trend toward better survival in patients without immunosuppressant use or ICI discontinuation.

“Although IRAEs are frequent and potentially severe, patients with pre-existing autoimmune disease are good candidates for ICI treatment,” according to the researchers, who recommended close follow-up and collaboration between oncologists and organ specialists in the management of this population.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]